A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped EMA/PDCO acknowledged that available results from this study do not support further clinical studies in relapsed/refractory AML paediatric patients.

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Phase1 and Phase 2: decitabine
DRUG: Phase 1: cytarabine
DRUG: Phase 2: cytarabine

Sponsor

Janssen Research & Development, LLC